Ex vivo evolution of human antibodies by CRISPR-X: from a naive B cell repertoire to affinity matured antibodies

BMC Biotechnol. 2019 Feb 18;19(1):14. doi: 10.1186/s12896-019-0504-z.

Marie-Claire Devilder^{1

2

3}, Melinda Moyon^{1

2}, Laetitia Gautreau-Rolland^{1

2}, Benjamin Navet^{1

2}, Jeanne Perroteau^{1

2}, Florent Delbos⁴, Marie-Claude Gesnel^{1

2

3}, Richard Breathnach^{5

6}, Xavier Saulquin^{7

8}

¹ CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
² LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.
³ Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France.
⁴ HLA Laboratory, EFS Centre Pays de la Loire, Nantes, France.
⁵ CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. [email protected].
⁶ LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France. [email protected].
⁷ CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France. [email protected].
⁸ LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France. [email protected].

No abstract available

Keywords: AID; CRISPR; CRISPR-X; Cytofluorimetry; HLA; Human antibodies; SHM; Tetramers.

Publication types